Background/Objectives: Riboflavin is a cofactor for the 5,10-methylenetetrahydrofolate reductase (MTHFR) enzyme involved in the homocysteine pathway. The aim of this study was to investigate the effects of maternal riboflavin intake and two MTHFR polymorphisms (677C4T; Ala222Val and 1298A4C; Glu429Ala substitutions) on the biomarkers of the homocysteine pathway, and investigate the risk of having offspring with an orofacial cleft (OFC). Subjects/Methods: In a case-control study design, dietary riboflavin intake and the MTHFR 677C4T and 1298A4C polymorphisms were evaluated in 123 OFC and 108 control mothers by using food frequency questionnaires and blood samples. Homocysteine (tHcy), folate and vitamin B12 concentrations in blood were analyzed in 70 cases and 68 controls. Linear and logistic regression analyses were applied. Results: At 14 months postpartum riboflavin intake and MTHFR 677C4T and 1298A4C genotypes were not significantly different between cases and controls. The 677TT genotype showed lower folate concentrations compared to C-allele carriers with a mean difference of 2.8 nmol/l in serum and 174 nmol/l in red blood cell (both P's ¼ 0.01). Every mg per day increase of dietary riboflavin intake was positively associated with increase in vitamin B12 concentration by 52.1% (Po0.01). This effect was most pronounced in MTHFR 677TT homozygotes (205.1%, P ¼ 0.03). The riboflavin-adjusted MTHFR 677TT and 1298CC genotypes showed a trend toward an increasing risk for OFC, adjusted odds ratio 1.7 (confidence interval (95% CI), 0.7-4.5) and 1.6 (95% CI, 0.7-4.2), respectively. Conclusions: Maternal riboflavin intake is significantly associated with biomarkers of the homocysteine pathway, with the strongest effects in MTHFR 677TT homozygotes. The maternal risk of having OFC offspring, however, is not associated with dietary riboflavin intake.
Introduction
Orofacial clefting (OFC) is a common congenital malformation with a worldwide prevalence rate of around 1 in 700 live births (International Clearinghouse Birth Defects Surveillance and Research, 2007) . Increasing evidence shows that both nutrients and genes are involved in the pathogenesis and prevention of OFC (Krapels et al., 2006) . A shortage of the nutrient folate can derange the homocysteine pathway resulting in hyperhomocysteinemia. Natural folate and synthetic folic acid treatment can restore this pathway .
5,10-Methylenetetrahydrofolate reductase (MTHFR, OMIM# 607093) is a prominent enzyme in the homocysteine pathway. It synthesizes 5-methyltetrahydrofolate and delivers methyl groups for the remethylation of homocysteine into methionine. The common 677C4T polymorphism in the MTHFR gene causes an amino-acid change (Ala222Val) resulting in an up to 65% reduced enzyme activity (Frosst et al., 1995) . The frequency of the MTHFR 677TT genotype varies from 3 to 32% in populations worldwide (Fodinger et al., 2000) . A second common polymorphism in the MTHFR gene (1298A4C) reports 1298CC frequencies of around 30-35% and decreases MTHFR enzyme activity as well (Frosst et al., 1995; Weisberg et al., 1998) .
Riboflavin or vitamin B2 is the precursor of the flavoenzymes flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) . It has been shown that inappropriate binding of FAD as a cofactor of thermolabile MTHFR results in reduced enzyme activity (Yamada et al., 2001) . FMN is a precursor in the synthesis of the downstream ligand of vitamin B12, which is a cofactor of methionine synthase implicated in the remethylation of homocysteine into methionine (Renz, 1970; Taga et al., 2007) .
Previously our group showed no association between riboflavin intake and OFC (Krapels et al., 2004) . Other studies have reported associations between riboflavin intake, MTHFR genotype and total plasma homocysteine (tHcy) (Jacques et al., 2002; McNulty et al., 2006) . From this background we aimed to investigate whether maternal dietary riboflavin intake in combination with the MTHFR 677C4T and 1298A4C polymorphisms (1) affects biomarkers of the homocysteine pathway, and (2) contributes to the risk of OFC offspring.
Subjects and methods

Study population
We analyzed the data from a Dutch case-control triad study, conducted between 1998 and 2001, of which the study design and population were described previously (van Rooij et al., 2003 Krapels et al., 2004) . Briefly, 198 mothers having a child with a nonsyndromic OFC and 191 control mothers were enrolled. Mothers were eligible for inclusion if the child had a nonsyndromic OFC, had not been adopted, and was between 9 and 18 months of age at the time of study. Mother, father and infant had to be Dutch Caucasians. To serve as controls, women recruited had a nonmalformed child, were of the same age range, were unrelated to the case families, and were living in the same geographic region as the case families. Maternal exclusion criteria were (1) pregnancy or breastfeeding at the time of study, (2) a reported change in dietary intake at the study time compared with the periconception period, (3) reported extreme nausea as hyperemesis or nausea starting after the first week of the index pregnancy with vomiting (OFC, n ¼ 52; control, n ¼ 67). Women of whom the food frequency questionnaire (FFQ) was missing were also excluded (OFC, n ¼ 23; control, n ¼ 16). This resulted in the analysis of 123 case and 108 control mothers. The study was approved by the central committee of medical research in the Hague, the Netherlands, and the medical ethical committees of all participating hospitals. Written informed consent was obtained from all the participants.
General characteristics
The following data were extracted from the general questionnaire filled out by the mother at the study moment The periconception period covered 4 weeks before up to 8 weeks after the conception of the index pregnancy. Data on periconception multivitamin intake, including folic acid supplements, and mild nausea and/or vomiting during the first trimester of pregnancy were used in the analysis.
Dietary data
Riboflavin intake was assessed using a validated FFQ developed for the Dutch cohorts of the European Prospective Investigation into Cancer and Nutrition study (Ocke et al., 1997a, b; Krapels et al., 2004) . Maternal dietary intake was collected at the study time, being between 9 and 18 months after the index pregnancy estimating the average intake of the 3 months. The underlying assumption is that dietary intake at the study moment is not different from periconception period of the index pregnancy, as confirmed by others (Willett et al., 1997; Devine et al., 2000; van Driel et al., 2009) . The period between the two time points covers approximately 24 months. This 2-year difference makes sure that the FFQ was filled out in the same season, minimizing the possibility of differential dietary intake due to seasonal variance (Leck et al., 1974) .
The FFQ was filled out by the mothers at home. The answers were given in frequency per day, week, month, year or never. The amount consumed was estimated in commonly used units by using household measures or colored photographs of foods showing different portion sizes. The researcher verified the completeness and consistency of the FFQ in a standardized way. Mean daily nutrient intake was estimated by multiplying the frequency of consumption of the food items by portion size and nutrient content per gram. Intake of total energy, macronutrients, vitamins and minerals was calculated by using the computerized version of the 1996 Dutch food composition table of the Netherlands Nutrition Centre (Netherlands Nutrition Centre, 1996) . The dietary riboflavin intake has been described previously in a larger group of cases and controls of the same study (Krapels et al., 2004) .
Blood sampling
From a subgroup of 70 case and 68 control mothers a venous blood sample was obtained to measure the concentrations of serum and red blood cell (RBC) folate, serum vitamin B12 and tHcy. Blood was taken in the morning after an overnight fast. Serum and RBC folate concentrations were measured with a microbiologic assay (Molloy and Scott, 1997) . The intra-and inter-assay coefficients of variation (CVs) were 6.1 and 10.2%, respectively. The IMx assay for serum vitamin B 12 was based on the microparticle enzyme immunoassay technology with intra-and interassay CVs of 5.7 and 6.3%, respectively (Kuemmerle et al., 1992) . Plasma tHcy concentrations were routinely determined by an automated highpressure liquid chromatography method with reverse phase separation and fluorescence detection with both an intra-assay and an inter-assay CV of less than 6.5% (te Poele-Pothoff et al., 1995) . For this study, vitamin B12 was routinely determined whereas folate and tHcy were measured in special runs. All laboratory analyses were performed blinded. In 5% blood parameters were missing due to failures in blood sampling or laboratory testing.
Assessment of the MTHFR polymorphisms
The MTHFR 677C4T polymorphism was determined in DNA from blood samples of 123 case and 108 control mothers. The MTHFR 1298A4C polymorphism was determined in blood samples of 100 case and 105 control mothers. Both MTHFR polymorphisms have been described previously in a larger group of cases and controls of the same study (van Rooij et al., 2003) .
Statistical analyses
At first, case and control mothers were evaluated with respect to age at delivery, energy intake and dietary riboflavin intake at the time of study by using Student's ttest. As the distribution was skewed, we applied natural logarithmic transformations and riboflavin intake was adjusted for energy (Willett et al., 1997) . Riboflavin intake is shown as mean with standard deviation. Differences in maternal education and the use of folic acid and multivitamin supplements with or without folic acid and/or riboflavin in the periconception period were tested by the w 2 -test. Differences in biomarkers between OFC and control mothers were evaluated with analysis of covariance (ANCOVA) and adjusted for vitamin supplement use and dietary folate intake at the time of study. These data are presented as medians with 5th and 95th percentiles.
The genotype distributions of the MTHFR polymorphisms between cases and controls were tested for Hardy-Weinberg equilibrium by the w 2 -test. Estimation of MTHFR haplotypes did not provide additional information to the study; the risk alleles excluded each other (data not shown).
To investigate the effects of the maternal MTHFR genotypes on the biomarkers of the homocysteine pathway, we pooled cases and controls, considering it is not very likely that the homocysteine pathway is differentially regulated in case and control mothers. Participants were stratified by MTHFR genotype, and the minor allele was selected as the risk allele. For MTHFR 677C4T, the participants were classified in TT homozygotes or C-allele carriers, and for MTHFR 1298A4C genotype, in 1298CC homozygotes or A-allele carriers. Differences in the logarithmic transformed biomarker concentrations between the MTHFR genotypes were evaluated using ANCOVA. Adjustments were made for vitamin supplement use and dietary folate intake at the time of study. In addition, in a linear regression model we adjusted the estimates for dietary vitamin B6 and B12 (data not shown) to exclude possible confounding by overlapping food sources.
Next, in a linear regression model we analyzed the effects of maternal riboflavin intake on the logarithmic transformed biomarkers, dependent of the MTHFR genotypes. Adjustments were made for dietary folate intake and vitamin use at the study moment and the estimates are expressed in percentage change of the biomarker per mg per day dietary riboflavin intake.
Finally, we calculated in a logistic regression model the risk estimates for both MTHFR polymorphisms with and without adjustment for dietary riboflavin intake in association with OFC offspring by odds ratio (OR) and 95% confidence interval (95% CI). MTHFR 677TT or 1298CC carriers were compared to their reference categories.
Results
The characteristics of the study groups are summarized in Table 1 . Maternal age at the time of delivery was comparable between the two groups, but educational level was lower in case mothers compared to controls (P ¼ 0.005). No significant differences were observed in energy-adjusted riboflavin intake and the periconception use of folic acid and/or multivitamin supplements. Serum folate and vitamin B12 were lower and tHcy was slightly higher in cases compared with controls. The allele frequencies and genotype distributions of both MTHFR variants were comparable in both groups. The genotype distributions in cases and controls were in Hardy-Weinberg equilibrium (MTHFR 677C4T, P ¼ 0.83; MTHFR 1298A4C, P ¼ 0.96). Table 2 shows dietary riboflavin intake and biomarker variables stratified for MTHFR genotypes. Riboflavin intake was not different between the various genotypes of both MTHFR polymorphisms (Table 2) . MTHFR 677TT homozygotes showed significantly lower serum and RBC folate concentrations after adjustment for dietary folate intake and vitamin supplement use at the time of study compared with MTHFR 677 C-allele carriers (P ¼ 0.01 for both biomarkers). No significant differences were found for tHcy and vitamin B12.
In Table 3 we show the relative changes in maternal biomarkers per mg intake of dietary riboflavin, adjusted for dietary folate intake and vitamin supplement use at the time In MTHFR 677TT carriers riboflavin intake showed a positive association with vitamin B12 (b ¼ 205.1%, P ¼ 0.03) and serum folate concentrations (b ¼ 75.9%, P ¼ 0.03). Vitamin B12 concentrations were much less affected by riboflavin intake in the MTHFR 677 C-allele carriers (b ¼ 33.1%, Po0.01). In MTHFR 1298A allele carriers the effects of riboflavin were marginal with a moderate mean decrease of tHcy with 16.5% (P ¼ 0.01), and increase of vitamin B12 by 49.5% (Po0.001) and folate in RBC with 26.7% (P ¼ 0.02). No differences in the biomarkers per mg per day of dietary riboflavin intake were observed in MTHFR 1298CC homozygotes.
In Table 4 the crude and adjusted risk estimates for OFC offspring are presented by maternal MTHFR 677C4T and 1298A4C genotypes. After adjustment mothers homozygous for the MTHFR 677TT or MTHFR 1298CC genotype showed a comparable increased OFC risk, albeit not statistically significant, OR 1.7 (95% CI, 0.7-4.5) and 1.6 (95% CI, 0.7-4.2), respectively.
Discussion
This study of mothers in reproductive ages shows that each mg per day dietary riboflavin intake is associated with a 52% increase in vitamin B12 concentrations. Furthermore, it Riboflavin, MTHFR and orofacial clefting M Vujkovic et al reveals that MTHFR 677TT homozygotes benefit most of riboflavin intake, because vitamin B12 and folate concentrations show an approximately twofold increase by every mg per day intake of dietary riboflavin. Independent effects of maternal dietary riboflavin intake were neither observed on OFC risk and nor in combination with both MTHFR polymorphisms.
In this study we observed that maternal dietary riboflavin intake increased vitamin B12 concentrations. This effect remained significant after adjusting for the other B vitamins and suggests that confounding by occurrence in common food sources is unlikely. This is in line with another study showing positive associations between dietary riboflavin intake and plasma vitamin B12 and folate (Konstantinova et al., 2007) .
Other studies reported inverse associations between riboflavin intake and tHcy (de Bree et al., 2001; McKinley et al., 2002; Konstantinova et al., 2007) . These findings are supported by others showing significant associations between riboflavin supplementation, MTHFR genotype and tHcy (Jacques et al., 2002; McNulty et al., 2006) . In our study this association was not observed. We believe that the inconsistency in these findings might be explained by dosage effects. We investigated riboflavin intake from dietary resources only as a determinant for tHcy with a medium daily intake of 1.68 mg. Other studies have investigated the effects of synthetic supplements in addition to the regular diet. By taking riboflavin-containing supplements, generally containing 0.8 mg riboflavin, in addition to the regular diet, the total riboflavin intake can easily exceed 2.0 g per day on average.
There are remarkable differences between the data of the European McNulty et al., 2006; Konstantinova et al., 2007) and US research on the effects of dietary riboflavin (Moat et al., 2003) . This is due to the fact that in the United States mandatory riboflavin fortification has been placed since 1940 and folic acid fortification in 1998. The impact of these policies is that in the general US population deficiencies of both nutrients will be limited and also in MTHFR 677TT carriers who appeared to be most sensitive for these shortages. In Europe, foods are not mandatory fortified with riboflavin and folate through which deficiencies can easily occur.
The MTHFR enzyme is a significant modifier in homocysteine remethylation, and its activity is decreased by genetic polymorphisms, folate intake and riboflavin as well. We observed a slight increase in RBC folate and decrease in tHcy as a result of the interaction between dietary riboflavin intake and MTHFR 677C4T genotypes. Thus, conclusions need to be made carefully when relating riboflavin intake to folate and tHcy blood concentrations and its effects on MTHFR activity. However, other studies support the hypothesis of riboflavin's favorable effects on tHcy in people with low folate concentrations and carrying the MTHFR 677TT genotype (Hustad et al., 2007) . Although the MTHFR 1298CC genotype also decreases enzyme activity, no effects were observed on biomarkers in our study and that of others (Weisberg et al., 1998; Friso et al., 2002) .
A limitation of our study is the lack of biomarker concentrations of riboflavin preferably determined in the form of erythrocyte glutathione reductase activation coefficient. We used riboflavin nutrient intake as proxy of the biochemical riboflavin status. Despite this drawback, our assumption is supported by two double-blind placebocontrolled intervention trials that revealed that riboflavin supplementation significantly improved concentrations of riboflavin and its derivatives in plasma and erythrocytes status (Hustad et al., 2002; McKinley et al., 2002) .
We show that polymorphisms in the maternal MTHFR 677C4T and 1298A4C genotype in combination with a low periconception dietary intake of riboflavin are not associated with a significantly increased OFC risk. Periconception folic acid supplementation has been shown to prevent OFC in some populations (Shaw et al., 1995; Hayes et al., 1996; van Rooij et al., 2004) . Our data and those of others may now suggest that a deranged homocysteine pathway due to impaired activity of the MTHFR enzyme can also be treated by additional intake of riboflavin (McNulty et al., 2006) . This assumption is in agreement with findings of an intervention study that showed that riboflavin intake or status may affect tHcy concentrations, but only in individuals with a lowfolate status and carrying the MTHFR 677TT genotype (Jacques et al., 2002) .
Selection and information bias represent major threats to the internal validity in case-control studies. We have observed that control mothers were in general higher educated than OFC mothers and possibly due to altruism they were more willing to participate. In the Netherlands, higher-educated mothers are more likely to use periconception folic acid and/or multivitamin supplements, and hence we observed a higher intake of vitamin supplements in control mothers compared with case mothers in this study, although the difference was not significant. To address this issue, we adjusted our analyses for maternal education and periconception folic acid and/or multivitamin supplement use, which did not significantly affect the risk estimates.
In general, differential recall bias of exposure is an issue of concern in case-control studies. However, in studies on birth defects recall bias may not be a major problem (Khoury et al., 1994; Infante-Rivard and Jacques, 2001; Delgado-Rodriguez and Llorca, 2004) . To avoid or at least minimize bias of dietary intake due to the time interval passed between the preconception period and the exposure assessment, FFQs were filled out at the time of study covering the dietary intakes of the previous 3 months. This study time has been used as a proxy for the intake during the preconception period and validated by our research group and others (Leck et al., 1974; Willett et al., 1997; Devine et al., 2000; van Driel et al., 2009) . Both time points cover the same seasonal period in year thereby minimizing the seasonal variance in dietary intake. Furthermore, women with a reported difference in dietary intake between these two periods were excluded from analysis, that is, 52 cases (26%) and 67 controls (35%). The frequencies of the excluded women in the case and control groups because of this reason were not significantly different. Therefore, in all analyzed case and control women the individual dietary intakes were comparable during the preconception and at the time of study. This makes it not very likely that neither case nor control mothers significantly altered their dietary intakes after pregnancy.
In conclusion, dietary riboflavin intake and MTHFR 677C4T genotypes affect vitamin B12 concentrations in mothers of reproductive age. The strong gene-nutrient interaction between riboflavin and MTHFR 677TT on vitamin B12 emphasizes the complexity of studying genenutrient interactions. Thus, we conclude that in countries without folic acid and riboflavin fortification the importance of the intake folate and B vitamins by women in reproductive ages should be more emphasized.
